Maintaining outstanding outcomes using response-and biology-based therapy for intermediate-risk neuroblastoma: A report from the Children's Oncology Group study …
CJ Twist, ML Schmidt, A Naranjo… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE The primary objective of the Children's Oncology Group study ANBL0531
(ClinicalTrials. gov identifier: NCT00499616) was to reduce therapy for subsets of patients …
(ClinicalTrials. gov identifier: NCT00499616) was to reduce therapy for subsets of patients …
[HTML][HTML] Outcome after reduced chemotherapy for intermediate-risk neuroblastoma
DL Baker, ML Schmidt, SL Cohn… - … England Journal of …, 2010 - Mass Medical Soc
Background The survival rate among patients with intermediate-risk neuroblastoma who
receive dose-intensive chemotherapy is excellent, but the survival rate among patients who …
receive dose-intensive chemotherapy is excellent, but the survival rate among patients who …
A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high‐risk neuroblastoma: an International Neuroblastoma Risk Group …
Background Long‐term outcome remains poor for children with high‐risk neuroblastoma
(five‐year overall survival [OS]∼ 50%). Our objectives were to (a) identify prognostic …
(five‐year overall survival [OS]∼ 50%). Our objectives were to (a) identify prognostic …
Outcomes of Children With Intermediate-Risk Neuroblastoma After Treatment Stratified by MYCN Status and Tumor Cell Ploidy
R Bagatell, P Rumcheva, WB London… - Journal of clinical …, 2005 - ascopubs.org
Purpose The goal of Pediatric Oncology Group 9243 was to improve outcomes for children
with intermediate-risk neuroblastoma (NB). Patients and Methods Patients were assigned to …
with intermediate-risk neuroblastoma (NB). Patients and Methods Patients were assigned to …
Improved outcome in children with newly diagnosed high-risk neuroblastoma treated with chemoimmunotherapy: updated results of a phase II study using hu14 …
WL Furman, B McCarville, BL Shulkin… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE We evaluated whether combining a humanized antidisialoganglioside
monoclonal antibody (hu14. 18K322A) throughout therapy improves early response and …
monoclonal antibody (hu14. 18K322A) throughout therapy improves early response and …
Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's …
WB London, R Bagatell, BJ Weigel, E Fox, D Guo… - Cancer, 2017 - Wiley Online Library
BACKGROUND Early‐phase trials in patients with recurrent neuroblastoma historically used
an objective “response” of measureable disease (Response Evaluation Criteria In Solid …
an objective “response” of measureable disease (Response Evaluation Criteria In Solid …
Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641
DR Strother, WB London, ML Schmidt… - Journal of clinical …, 2012 - ascopubs.org
Purpose The primary objective of Children's Oncology Group study P9641 was to
demonstrate that surgery alone would achieve 3-year overall survival (OS)≥ 95% for …
demonstrate that surgery alone would achieve 3-year overall survival (OS)≥ 95% for …
Children's Oncology Group's 2023 blueprint for research: neuroblastoma
R Bagatell, SG DuBois, A Naranjo, J Belle… - Pediatric Blood & …, 2023 - Wiley Online Library
Neuroblastoma is the most common extra‐cranial solid tumor in children and is known for its
clinical heterogeneity. A greater understanding of the biology of this disease has led to both …
clinical heterogeneity. A greater understanding of the biology of this disease has led to both …
Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12-to 18-Month Change in Age Cutoff in Children's Oncology Group …
HG Bender, MS Irwin, MD Hogarty… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE In 2006, Children's Oncology Group (COG) reclassified subgroups of toddlers
diagnosed with neuroblastoma from high-risk to intermediate-risk, when the age cutoff for …
diagnosed with neuroblastoma from high-risk to intermediate-risk, when the age cutoff for …
[HTML][HTML] Stage 4 s neuroblastoma: features, management and outcome of 268 cases from the Italian Neuroblastoma Registry
B De Bernardi, A Di Cataldo, A Garaventa… - Italian Journal of …, 2019 - Springer
Background Infants diagnosed with stage 4 s neuroblastoma commonly experience
spontaneous disease regression, with few succumbing without response to therapy. We …
spontaneous disease regression, with few succumbing without response to therapy. We …